Disseminated Saksenaea infection in an immunocompromised host associated with a good clinical outcome: a case report and review of the literature.
Amphotericin B
Disseminated fungal infection
Mucormycosis
Posaconazole
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
14 Oct 2020
14 Oct 2020
Historique:
received:
21
12
2019
accepted:
29
09
2020
entrez:
15
10
2020
pubmed:
16
10
2020
medline:
11
11
2020
Statut:
epublish
Résumé
Saksenaea species (spp.) are uncommon causes of mucormycosis but are emerging pathogens mostly associated with trauma and soil contamination often in immunocompetent hosts. Due to lack of sporulation in the laboratory, diagnosis and susceptibility testing is difficult so optimal treatment regimens are unknown. A 67 year-old man from the Northern Territory in Australia, with a history of eosinophilic granulomatosis with polyangiitis, developed disseminated Saksenaea infection after initially presenting with symptoms consistent with bacterial pyelonephritis. Despite a delay in diagnosis; with aggressive surgical management and dual therapy with amphotericin B and posaconazole, he survived. We describe an unusual case of disseminated infection with a favourable outcome to date.
Sections du résumé
BACKGROUND
BACKGROUND
Saksenaea species (spp.) are uncommon causes of mucormycosis but are emerging pathogens mostly associated with trauma and soil contamination often in immunocompetent hosts. Due to lack of sporulation in the laboratory, diagnosis and susceptibility testing is difficult so optimal treatment regimens are unknown.
CASE PRESENTATION
METHODS
A 67 year-old man from the Northern Territory in Australia, with a history of eosinophilic granulomatosis with polyangiitis, developed disseminated Saksenaea infection after initially presenting with symptoms consistent with bacterial pyelonephritis. Despite a delay in diagnosis; with aggressive surgical management and dual therapy with amphotericin B and posaconazole, he survived.
CONCLUSIONS
CONCLUSIONS
We describe an unusual case of disseminated infection with a favourable outcome to date.
Identifiants
pubmed: 33054720
doi: 10.1186/s12879-020-05459-9
pii: 10.1186/s12879-020-05459-9
pmc: PMC7559758
doi:
Substances chimiques
Antifungal Agents
0
Triazoles
0
posaconazole
6TK1G07BHZ
Amphotericin B
7XU7A7DROE
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
755Références
Curr Infect Dis Rep. 2010 Nov;12(6):423-9
pubmed: 21308550
J Fungi (Basel). 2019 Nov 14;5(4):
pubmed: 31739583
Emerg Infect Dis. 2008 Feb;14(2):342-4
pubmed: 18258139
Clin Microbiol Infect. 2016 Sep;22(9):775-781
pubmed: 26806139
J Infect. 1983 Sep;7(2):162-5
pubmed: 6644085
Am J Clin Pathol. 1981 Jul;76(1):116-21
pubmed: 6942651
Nucleic Acids Res. 2016 Jan 4;44(D1):D7-19
pubmed: 26615191
Clin Infect Dis. 2000 Jun;30(6):942-3
pubmed: 10880307
J Mycol Med. 2019 Sep;29(3):260-264
pubmed: 31445820
Antimicrob Agents Chemother. 2002 May;46(5):1581-2
pubmed: 11959605
Med Mycol. 2012 Oct;50(7):710-5
pubmed: 22458251
J Clin Microbiol. 2010 Dec;48(12):4410-6
pubmed: 20926710
Mycopathologia. 2014 Feb;177(1-2):97-101
pubmed: 24178374
Mycopathologia. 2020 Jun;185(3):577-581
pubmed: 32279162
Clin Microbiol Rev. 2011 Apr;24(2):411-45
pubmed: 21482731
Int J Microbiol. 2019 Sep 22;2019:6253829
pubmed: 31662760
Med J Aust. 2008 Nov 3;189(9):519-20
pubmed: 18976196
Sabouraudia. 1985 Apr;23(2):137-40
pubmed: 4012512
J Fungi (Basel). 2019 Mar 21;5(1):
pubmed: 30901907